Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Genia Long

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Medical Economics|June 14, 2019
Federal government-interest patent disclosures for recent top-selling drugsGenia Long
Journal of Medical Economics|March 25, 2026
Trends in industry-sponsored clinical trial activity since passage of the Inflation Reduction ActGenia Long
Journal of Medical Economics|February 29, 2024
Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction ActHenry Grabowski, Genia Long
Expert Opinion on Therapeutic Patents|May 1, 2015
The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticalsIain Cockburn, Genia Long
Journal of Medical Economics|December 11, 2013
Recent trends in brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard Mortimer
Pharmacoeconomics|May 27, 2020
Financing Drug Innovation in the US: Current Framework and Emerging ChallengesDavid Cutler, Noam Kirson, Genia Long
Health Affairs (Project Hope)|September 13, 2006
The market for follow-on biologics: how will it evolve?Henry Grabowski, Iain Cockburn, Genia Long
Nature Reviews. Drug Discovery|January 4, 2011
Data exclusivity for biologicsHenry Grabowski, Genia Long, Richard Mortimer
Seton Hall Law Review|July 12, 2011
Implementation of the biosimilar pathway: economic and policy issuesHenry Grabowski, Genia Long, Richard Mortimer
Journal of Medical Economics|September 16, 2014
Evolving provider payment models and patient access to innovative medical technologyGenia Long, Richard Mortimer, Geoffrey Sanzenbacher
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Medical Economics|June 14, 2019
Federal government-interest patent disclosures for recent top-selling drugsGenia Long
Journal of Medical Economics|March 25, 2026
Trends in industry-sponsored clinical trial activity since passage of the Inflation Reduction ActGenia Long
Journal of Medical Economics|February 29, 2024
Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction ActHenry Grabowski, Genia Long
Expert Opinion on Therapeutic Patents|May 1, 2015
The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticalsIain Cockburn, Genia Long
Journal of Medical Economics|December 11, 2013
Recent trends in brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard Mortimer
Pharmacoeconomics|May 27, 2020
Financing Drug Innovation in the US: Current Framework and Emerging ChallengesDavid Cutler, Noam Kirson, Genia Long
Health Affairs (Project Hope)|September 13, 2006
The market for follow-on biologics: how will it evolve?Henry Grabowski, Iain Cockburn, Genia Long
Nature Reviews. Drug Discovery|January 4, 2011
Data exclusivity for biologicsHenry Grabowski, Genia Long, Richard Mortimer
Seton Hall Law Review|July 12, 2011
Implementation of the biosimilar pathway: economic and policy issuesHenry Grabowski, Genia Long, Richard Mortimer
Journal of Medical Economics|September 16, 2014
Evolving provider payment models and patient access to innovative medical technologyGenia Long, Richard Mortimer, Geoffrey Sanzenbacher
Pageof 3